Evidence map›Paper›PMID 39749216›Full record

ArticleFrontiers in molecular biosciences2024

Development of 6-amido-4-aminoisoindolyn-1,3-diones as p70S6K1 inhibitors and potential breast cancer therapeutics.

Adrian Thornton, Rajesh Komati, Hogyoung Kim, Jamiah Myers, Kymmia Petty, Rion Sam, Elijah Johnson-Henderson, Keshunna Reese, Linh Tran, Vaniyambadi Sridhar and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular biosciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Adrian ThorntonDepartment of Chemistry, Xavier University of Louisiana, New Orleans, LA, United States.
Rajesh KomatiDepartment of Chemistry, Nicholls State University, Thibodaux, LA, United States.
Hogyoung KimDivision of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA, United States.
Jamiah MyersDepartment of Chemistry, Xavier University of Louisiana, New Orleans, LA, United States.
Kymmia PettyDepartment of Chemistry, Xavier University of Louisiana, New Orleans, LA, United States.
Rion SamDepartment of Chemistry, Xavier University of Louisiana, New Orleans, LA, United States.
Elijah Johnson-HendersonDepartment of Chemistry, Xavier University of Louisiana, New Orleans, LA, United States.
Keshunna ReeseDepartment of Chemistry, Xavier University of Louisiana, New Orleans, LA, United States.
Linh TranDepartment of Chemistry, Xavier University of Louisiana, New Orleans, LA, United States.
Vaniyambadi SridharDepartment of Biology, University of New Orleans, New Orleans, LA, United States.
Christopher WilliamsDivision of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA, United States.
Jayalakshmi SridharDepartment of Chemistry, Xavier University of Louisiana, New Orleans, LA, United States.

Funding

Xavier RCMI Renewal Application-Research Infrastructure CoreU54MD007595 · NIMHD · XAVIER UNIVERSITY OF LOUISIANA · PI Guangdi Wang, Christopher Williams · 2019 to 2026
$41.9M
Building Integrated Pathways to Independence for Diverse Biomedical ResearchersUL1GM118967 · NIGMS · XAVIER UNIVERSITY OF LOUISIANA · PI FOROOZESH, MARYAM, GIGUETTE, MARGUERITE · 2015 to 2023
$17.7M
PROJECT PATHWAYS: STUDENT TRAINING CORETL4GM118968 · NIGMS · XAVIER UNIVERSITY OF LOUISIANA · PI FOROOZESH, MARYAM, GIGUETTE, MARGUERITE · 2015 to 2023
$9.2M
Project Pathways: Research Enrichment CoreRL5GM118966 · NIGMS · XAVIER UNIVERSITY OF LOUISIANA · PI FOROOZESH, MARYAM, GIGUETTE, MARGUERITE · 2015 to 2023
$6.6M
NIGMS NIH HHS RL5 GM118966NIGMS NIH HHS TL4 GM118968NIGMS NIH HHS UL1 GM118967NIMHD NIH HHS U54 MD007595
6 · The paper itself

Abstract

Introduction: Many breast cancer therapeutics target the PI3K/AKT/mTOR oncogenic pathway. Development of resistance to the therapeutics targeting this pathway is a frequent occurrence. Therapeutics targeting p70S6K1, a downstream member of this pathway, have recently gained importance due to its critical role in all types of breast cancer and its status as a prognostic marker. We have developed a new class of p70S6K1 inhibitors that show growth inhibition of MCF7 breast cancer cells. Methods: A series of 6-amido-4-aminoisoindolyn-1,3-dione compounds was developed against p70S6K1 using docking, computational modeling tools, and synthesis of the designed compounds. The p70S6K1 inhibition potency of the compounds was investigated in an initial high-throughput screening followed by IC Results: In this study, we have identified a new class of compounds as p70S6K1 inhibitors that function as growth inhibitors of MCF7 breast cancer cells. The structural features imparting p70S6K1 inhibition potency to the compounds have been mapped. Our studies indicate that substitutions on the phenacetyl group residing in the cleft A of the protein do not contribute to the inhibition potency. Three compounds (

Indexed as

breast cancerdocking studiesinhibitionpotencyprotein kinase

Identifiers

PMID39749216
PMCPMC11694070

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.